Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
about
How does surgery compare with advanced intra-articular therapies in knee osteoarthritis: current thoughtsCytokines as biochemical markers for knee osteoarthritis.Influence of pain severity on health-related quality of life in Chinese knee osteoarthritis patients.Predicting Knee OsteoarthritisCost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee.Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States.Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?Emerging drugs for the treatment of knee osteoarthritis.Identification of factors associated with the development of knee osteoarthritis in a young to middle-aged cohort of patients with knee complaints.Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.Cost-Utility of a Single-Injection Combined Corticosteroid-Hyaluronic Acid Formulation vs a 2-Injection Regimen of Sequential Corticosteroid and Hyaluronic Acid Injections.Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and Obesity.Cost effectiveness of training rural providers to perform joint injections.Comparison of the 3 Different Injection Techniques Used in a Randomized Controlled Study Evaluating a Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) for Osteoarthritis of the Knee: A Subgroup Analysis.Glucosamine and chondroitin for the treatment of osteoarthritis.A Fresh Perspective on a Familiar Problem: Examining Disparities in Knee Osteoarthritis Using a Markov Model.The individual and socioeconomic impact of osteoarthritis.Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?Intra-articular Recombinant Human Proteoglycan 4 Mitigates Cartilage Damage After Destabilization of the Medial Meniscus in the Yucatan Minipig.
P2860
Q26744338-FDF5B472-F66B-4AFC-92E8-91AF61FAFBEBQ35003515-97EEE8EB-F897-41CD-BF9A-30616F8F2E49Q35644139-52D03FFB-92E9-4F39-8A14-67F3AD64F628Q36403388-C86E192E-24E5-44E6-912F-A48C5FBF6D51Q36600338-0F370F77-CAC2-42DA-91D8-0967409C6231Q36890872-1E6E73CA-0ECA-49F6-9C9A-43F69107EBB1Q37118807-59A03107-5529-4164-B36C-EB9AFE3BE6EBQ37447599-7BACA722-D4A3-4730-BEE0-CFF5D75230F3Q37735333-F1E9C54A-4F36-440E-B8E7-F0EB0D1E075EQ38417521-A07376CA-A002-4548-B4CD-5AFB0BEBCED1Q39130600-DDD1FBC3-B19C-4B3E-8947-8D295A47C558Q39152377-E02357F1-2875-4270-9131-72CE49222C5FQ39153895-775A403A-339A-4926-AAA1-9CE2D87B7ED9Q39173569-66126C01-5DED-4905-B475-27C057BAD305Q39889169-3E319169-C7D8-429F-B6BF-16B04400DEF8Q40142330-CCAA0B5E-455F-4AE5-B688-11FBABB78349Q41443426-D4529EC5-1DEC-40E9-A11F-1107D194269EQ42330053-127BC6A1-53AB-465C-B50D-B73D4C5F1D86Q42697105-E5D40CE1-7726-46FE-B311-CE13A11F87C7Q47602911-98FA5F7D-992E-445B-9F8A-855942E6DD8EQ47709852-95F363DB-34F7-4325-91F7-8590BF2CBF54Q50209593-2DC1712B-4F93-453B-A0E8-D93D3F74A4DD
P2860
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
@en
type
label
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
@en
prefLabel
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
@en
P2093
P2860
P50
P1476
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
@en
P2093
A D Paltiel
D H Solomon
J M Jordan
M E Daigle
S A Burbine
P2860
P304
P356
10.1016/J.JOCA.2013.01.016
P577
2013-02-04T00:00:00Z